Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCADIA: Apixaban vs Aspirin for Cryptogenic Stroke
NCT03192215Phase 3Terminated
- Sponsor
- Columbia University
- Start
- Jan 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of apixaban in ischemic stroke (2 arms), sponsored by Columbia University. Primary endpoint: Recurrent Stroke of Any Type up to 5 years. Started Jan 2018; status: terminated.
02
Drugs
apixaban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03192215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192215.